Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 48,563 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Chronic Sinusitis, Facial Pain Disorder, Depression
Interventions: escitalopram, placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ADHD, Perinatal, Behavioral Intervention
Interventions: MomMA Intervention, Treatment as Usual (TAU); Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Nephropathy
Interventions: CTP-499; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Obsessive-Compulsive Disorder
Interventions: Cognitive bias modification for interpretation bias, Psychoeducation; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Myelodysplastic Syndrome
Interventions: 5-azacytidine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Telemedicine, Survey administration, Electronic health record review, Best Practice; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: REGN910-3, Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more

Conditions: Cushing Syndrome, Endocrine Disease
Interventions: Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG; Drug · Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Opioid Dependence, Methadone Withdrawal Syndrome
Interventions: Lofexidine HCl, Lofexidine-matching sugar pill; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pancreatic Adenocarcinoma
Interventions: Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800; Procedure · Biological · Drug
Lead sponsor: George Poultsides; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy
Interventions: Radio-labeled rodatristat ethyl 600 mg; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: AMV564 14-Day CIV; Drug
Lead sponsor: Amphivena Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Duarte, California • Tampa, Florida • St Louis, Missouri + 2 more

Conditions: Neuropathy;Peripheral
Interventions: EXCAP Exercise, Nutrition Education Control; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diabetes
Interventions: Community health worker education, Cell phone text messaging; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years to 64 Years
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postoperative Nausea and Vomiting
Interventions: APD421, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Columbus, Ohio

Conditions: Breast Neoplasms, Psychology, Social
Interventions: Peer Support Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Multiple Locations, California

Conditions: Specific Phobia, Animal
Interventions: Augmented reality exposure therapy; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy Volunteers
Interventions: Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Migraine
Interventions: Thermal stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) response, PedMIDAS (Pediatric Migraine Disability Assessment), Hormonal assessment, Pubertal status; Device · Behavioral · Diagnostic Test + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 11 Years to 15 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Executive Function, Behavioral Research, Schools, Behavior Therapy
Interventions: Organizational Skills Training - Tier 2 (OST-T2); Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
Interventions: Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Irinotecan; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more

Conditions: Androgenetic Alopecia
Interventions: Minoxidil, Placebo; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: TG-2349 as the original formulation, TG-2349 as a new capsule formulation; Drug
Lead sponsor: TaiGen Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

Sinusitis and Facial Pain Disorders Anti-Depression Trial

Expectant Moms Managing Attention-Deficit/ Hyperactivity Disorder

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Interpretation Bias as a Mechanism of Treatment Response in OCD

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Exercise and Nutrition Interventions During Chemotherapy

Controlling Hyperglycemia Among Minority Population

Study of APD421 as PONV Treatment (no Prior Prophylaxis)

Nuevo Amanecer: Promoting the Psychosocial Health of Latinas

Bringing Exposure Therapy to Real-Life Context With Augmented Reality-Dogs (ARET)-Dogs

A Study of Danavorexton in Anesthetized Adults

Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine

Organizational Skills Training - Tier 2 (OST-T2)

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Microarray Analysis of Scalp Biopsies After Minoxidil Treatment

Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers